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A natriuretic factor has been described in the specific granules of rat atria. We have purified three factors 
which seem to be low-M, peptides. They have been purified by means of acid extraction, octadecyl Sep-Pak 
cartridges, and chromatography on Bio-Gel P-10, CM Bio-Gel A, Mono S and reverse-phase high- 
performance liquid chromatography columns. The factors contain 26,31 and 33 amino acids and may have 
been partially degraded during isolation. They are all 3 biologically active and the shorter one is the most 
active with a specific activity of 450000 units/mg. 
Atria1 natriuretic factor Natriuresis 
1. INTRODUCTION 
A rat atria1 natriuretic factor (ANF) was first 
described by authors in [ 11, who found that the in- 
jection of atria1 homogenates induced marked 
diuresis and natriuresis in the rat. Subsequent 
work has shown that the ANF is localized in the 
granules of the atria1 cardiocytes [2,3]. Purifica- 
tion of ANF and its partial characterization in- 
dicated that it consists chiefly of a basic peptide of 
molecular mass about 5000 [4-61. However, 
heterogeneity was observed and some studies have 
indicated the presence of larger molecules of active 
material [4,6-91. We report the complete purifica- 
tion of 3 biologically active atria1 natriuretic fac- 
tors and their amino acid composition. 
2. MATERIALS AND METHODS 
2.1. Purification of ANF 
Atria from female or male Sprague-Dawley rats 
were homogenized (1 g/10 ml) in 1 M acetic acid 
containing 1 mM EDTA, 1 mM phenylmethyl 
sulfonyl fluoride and 12.5 ,uM pepstatin. After 
centrifugation at 30000 x g for 20 min, the super- 
natant was frozen at -20°C overnight, thawed 
and centrifuged at 100000 x g for 30 min. The 
Diuresis Peptide purification 
final supernatant was passed through octadecyl 
Sep-Pak cartridges (1 cartridge/2 g of atria) and 
the active material was deposited on a Bio-Gel 
P-10 column (2.5 x 90 cm) and eluted with 0.1 M 
acetic acid. The active material from this column 
was clearly separated into two active regions of dif- 
ferent molecular masses (4000-6000 and 
6000-15 000). Each pooled region was further 
purified separately. The active material was next 
applied to a CM Bio-Gel A column (1.5 x 30 cm) 
and eluted with a linear gradient of 450 ml of 
0.01-1.0 M ammonium acetate, pH 5.0. ANF was 
then purified on a Mono S HR5/5 column (Phar- 
macia Fine Chemicals) adapted to be used on a li- 
quid chromatograph (Varian Model 5060). A gra- 
dient of 0.02-l .O M triethylamine acetate (pH 6.5) 
was used. Two-minute fractions were collected. 
With the low A4* material the most active compo- 
nent was eluted with 0.9 M buffer, but the most 
active of the high-M, factors was eluted with about 
0.8 M buffer. Low-M, natriuretic factor was 
subsequently purified by reverse-phase high per- 
formance liquid chromatography (HPLC) in the 
following sequence: CN PBondapak (Waters 
Associates) (0.39 x 30 cm) 0.1% (v/v) 
trifluoroacetic acid in CH3CN at 0°C; Cis PBon- 
dapak (Waters Associates) (0.39 x 30 cm) 0.1% 
286 
Published by Elsevier Science Publishers B. V. 
00145793/83/$3.00  1983 Federation of European Biochemical Societies 
Volume 164, number 2 FEBS LETTERS December 1983 
(v/v) trifluoroacetic acid in CH3CN at room 
temperature: C18 PBondapak (Waters Associates) 
(0.39 x 30 cm) 0.13% (v/v) heptafluorobutyric 
acid in CH3CN at room temperature. This active 
material was designated as ANF-I. 
The high-M* natriuretic factor was passed 
through a Bio-Sil TSK IEX-530 CM column (Bio- 
Rad Laboratories) (0.4 x 30 cm) and eluted with a 
linear gradient of 0.02 M-O.4 M ammonium for- 
mate (pH 5.0) containing 15% CH3CN with a 
slope of 0.008 M/min and a flow rate of 
0.7 ml/min. The active peak was finally purified 
by reverse-phase HPLC on a CN PBondapak col- 
umn as described above. Two major active peaks 
were found and designated ANF-II and ANF-III. 
When possible, all steps were carried out at 4°C. 
At the end of each chromatographic step the 
material was lyophilized. For small volumes 
(~6 ml) lyophilization was carried out in 
polystyrene tubes (1.5 x 7 cm) in a Savant Speed 
Vat concentrator. Larger volumes in the first steps 
were lyophilized in glass flasks. Samples were 
dissolved in l-3 ml of 0.01 M ammonium acetate, 
pH 5.0. Aliquots were taken for the biological 
assay [2,4], which was done in duplicate. Proteins 
were measured by the Bradford assay [lo] with 
bovine albumin as a standard, except in the last 
step where the amount of peptide was estimated 
from the amino acid analyzer. 
2.2. Carboxymethylation of ANF 
The cysteine residues were reduced with 
dithiothreitol as in [l I]. Reduced cysteines were 
then alkylated with iodoacetic acid. The peptide 
was desalted on a Cl8 FBondapak column, using 
0.1% trifluoroacetic acid in CH&N. 
2.3. Amino acid analysis 
Amino acid analysis was performed on 5 ,ug of 
each carboxymethylated peptide after 22 h of 
hydrolysis at 105°C in 5.7 N HCl and 0.1% mer- 
captoethanol. The amino acids were separated in a 
modified 120C-Beckman amino acid analyzer us- 
ing a Beckman W3 or Dionex DCSA column [12]. 
3. RESULTS AND DISCUSSION 
For this study, 27 g atria (320 rats) were used. 
The initial homogenate contained an activity 
equivalent to 840000 pmol of Na+ excreted per 
20 min (here called 840000 units), as measured by 
bioassay, with a specific activity of 360 units/mg 
protein. At the Bio-Gel P-10 step about half of the 
active material corresponded to a low-M, 
(4000-6000) natriuretic substance. The elution 
pattern for the low-M, natriuretic factor on the 
Mono S is shown in fig. 1. Although active material 
was found in almost all fractions, indicating the 
heterogeneity of the product, most of the activity 
was found in the 40- to 44-min fractions. At this 
step, the yield is less than 5070, and ANF-I has a 
specific activity of 13 1000 units/mg. These results 
are similar to those published earlier [4]. However, 
to achieve further purification we used reverse- 
phase HPLC. Fig.2 illustrates the elution of the 
ANF-I on the CN FBondapak column. Although 
we were able to identify a peak with natriuretic ac- 
tivity, the specific activity of the material 
recovered was much lower than in the preceding 
step (84000 units/mg), which indicates partial in- 
activation of the peptide. The peptide ANF-I was 
0.1 r I 
0.08 
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Fig.1. Elution of the low-M, active material from the 
CM Bio-Gel A column off a Mono S HR5/5 column 
with a concentration gradient of triethylamine acetate, 
pH 6.5. Flow rate, 1 ml/min: 2-min fractions collected. 
The slowest fractions, collected at 40-44 min, were 
together designated ANF-I. 
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Fig.2. Chromatography of ANF-I on CN pBondapak, 
eluted with acetonitrile 20-50% in 0.1% trifluoroacetic 
acid at a gradient of 0.25%/min and a flow rate of 
1 ml/min. The shaded area indicates the peak with 
natriuretic activity. 
then applied to a Cl8 PBondapak column eluted 
with a gradient of 0.1% trifluoroacetic acid in 
acetonitrile (0.2%/min, 1 ml/min) and finally to 
the same column, but with 0.13% hep- 
tafluorobutyric acid instead of 0.1% trifluoro- 
acetic acid (fig.3). In the two last steps the peptide 
appeared as a single peak. The final yield of ANF-I 
was about 120,~g. 
The high-n/l, natriuretic factor was eluted on the 
Mono S with 0.8 M buffer. The elution pattern, as 
for the low-M, factor, indicated considerable 
heterogeneity. Only the purest fractions were pool- 
ed. On the Bio-Sil column the material was eluted 
with 0.3 M ammonium formate. In the last step 
(fig.4), the CN PBondapak column, two major 
peaks were seen and denoted ANF-II and ANF-III 
with a final yield of 30 and 20 pg, and specific ac- 
tivities of 450000 and 297000 units/mg, 
respectively. 
The amino acid compositions of carbox- 
ymethylated ANF-I, ANF-II and ANF-III are 
given in table 1. These data suggest hat the 3 pep- 
tides are very similar and contain mostly 
hydrophobic and basic amino acids. Similar results 
were reported in [6], but the peptide purified there 
seems to be longer (49 amino acids). 
ANF-I and ANF-II are probably shorter pep- 
tides. The presence of these 3 peptides and the 
heterogeneity encountered after the gel filtration 
and the Mono S column may be due to proteolytic 
0.08 
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Cl8 /A BONOAPAK 
HFBA O.r3%, lmllmin 
0.20% CH,CN/mm 
TIME (mm) 
Fig.3. Chromatography of the purified peptide ANF-I on CNr8 PBondapak, eluted with acetonitrile 20-50% in 0.13% 
heptafluorobutyric a id at a gradient of 0.2070/min a d a flow rate of 1 mI/min. 
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Fig.4. Chromatography of the high-W material on CN 
pBondapak, eluted with acetonitrile 20-50% in 0.1% 
trifluoroacetic acid at a gradient of 0.375%/min and a 
flow rate of 1 ml/min. The shaded areas indicate the 
peaks with natriuretic activity. The major peaks were 
designated ANF-II and ANF-III. 
digestion in the homogenate. Moreover the fact 
that ANF-II and ANF-III, purified from the high- 
M, region, nevertheless have about the same M,- 
value as ANF-I from the low-M, fraction, may in- 
dicate artefact formation due to adsorption during 
gel filtration. 
The 3 purified peptides were biologically active 
after the CN PBondapak column. A dose range of 
0.15-0.75 nmol, depending on the peptide, will in- 
duce a lo-fold increase in urine output and a 
20-fold increase in sodium excretion when injected 
intravenously into a rat. ANF-II, the shortest one, 
was the most active, which suggests that some 
parts of the amino acid sequence of ANF-I and 
ANF-III may not be essential for the activity. 
In conclusion we have isolated 3 pure peptides 
which cause natriuresis and diuresis in the rat. 
Further studies on the amino acid sequence will in- 
dicate relationships between the structures of these 
peptides and their biological activities. 
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Table 1 
Amino acid compositions of ANF peptide$’ 
Amino acid 
residue 
ANF-I ANF-II ANF-III 
Asx 
Ser 
Glx 
Pro 
GlY 
Ala 
Be 
Leu 
Tyr 
Phe 
Arg 
cyst 
Trp* 
2.17 (2)b 2.06 (2) 2.13 (2) 
4.61 (5) 3.57 (4) 4.53 (5) 
1.26 (1) 1.29 (1) 1.38 (1) 
1.08 (1) - 1.02 (1) 
6.00 (6) 4.97 (5) 6.16 (6) 
1.14 (1) 1.14 (1) 2.07 (2) 
1.97 (2) 1.93 (2) 1.91 (2) 
2.15 (2) 1.19 (1) 3.17 (3) 
0.69 (1) 0.98 (1) 1.00 (1) 
2.22 (2) 2.03 (2) 2.06 (2) 
6.19 (6) 4.83 (5) 5.86 (6) 
1.86 (2) 2.00 (2) 1.71 (2) 
ND ND ND 
Total 31 26 33 
a Amino acid analysis was performed on reduced and 
alkylated ANF-I, ANF-II and ANF-III 
b Numbers in parentheses give the nearest integer 
’ Cys was quantitated as the sum of Cys, 
carboxymethylCys and cysteic acid 
* ND, not determined 
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